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Myoepithelial cells (MEs), which surround ducts and acini of the breast glands, exhibit an anti-invasive phenotype and form a natural
border separating proliferating tumour cells of ductal carcinoma in situ (DCIS) from basement membrane (bm) and underlying
stroma. Invasion requires penetration of these host cellular and extracellular matrix barriers. This destruction is caused by proteolytic
activity of tumour cells and host bystander cells. There is substantial evidence that high concentrations of the urokinase plasminogen-
activating system are conducive to tumour cell spread and metastasis. Prompted by the conspicuous absence of studies examining the
role of the ME in breast cancer progression, we studied the expression of the urokinase plasminogen activator receptor (uPAR) and
plasminogen activator inhibitor type-1 (PAI-1) in MEs of 60 DCIS samples. Our results show that nearly all MEs of DCIS and normal
breast glands exhibit the uPAR antigen, whereas the PAI-1 antigen was mainly expressed in MEs of high-grade DCIS. In one
intermediate DCIS numerous ducts showed an incomplete myoepithelial layer expressing uPAR and PAI-1. We conclude that uPAR
in MEs may be necessary to attach them to the bm by uPAR/vitronectin (Vn) interaction. The strong expression of PAI-1, which is
known to resolve the uPAR/Vn binding, may be involved in the detachment of MEs of DCIS. Although the role of PAI-1 acting as cell
detachment factor could not be demonstrated in our study, we speculate that the loss of the anti-invasive ME layer in DCIS may be
triggered by PAI-1 and could be an early sign of subsequent tumour cell infiltration.
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Ductal carcinoma in situ (DCIS) is a proliferation of malignant
epithelial cells within the ductulolobular system of the breast that
shows no evidence of invasion through the basement membrane
(bm) into the surrounding stroma. For tumour progression and
metastasis cancer cell invasion is necessary (Silverstein, 1998). The
growth and development of invasive breast cancer is determined
not only by the specific oncogenic or tumour suppressor
alterations occurring within the malignant cell itself, but also by
paracrine regulation exerted by many host bystander cells
including fibroblasts, macrophages, and endothelial cells. One
host cell type, however, the myoepithelial cell (ME), has not been
studied in depth. Myoepithelial cells in vivo surround the ducts
and acini of the breast and contribute to the synthesis of a
surrounding bm. This anatomic relationship suggests that MEs
may exert significant paracrine effects on breast epithelium, which
regulate the progression of DCIS to invasive breast cancer
(Sternlicht et al, 1997). Tumour cells cross host cellular and
extracellular matrix barriers during tumour invasion and metas-
tasis by attachment to and interaction with components of the bm
and the extracellular matrix and by cellular proteolysis (Schmitt
et al, 1997).
In retrospective studies, pathologists have noted an approximate
25% incidence of progression of DCIS to invasive cancer over a 6-
to 10-year period (Page et al, 1982), but whether genetic events in
DCIS or paracrine events governed by the myoepithelial or other
host cell influence this progression is not known. It is believed that
MEs are an important paracrine regulator of breast carcinoma
progression and that MEs exert an anti-invasive role on the
progression of DCIS. The high constitutive expression of the
tumour suppressor maspin and diverse proteinase inhibitors,
accompanied by low levels of proteinase expression provide
support for this anti-invasive role for the ME (Sternlicht et al,
1997). It is not known whether a loss of the ME layer in DCIS is an
early sign of subsequent invasion.
Determination of components of the plasminogen activator
system in breast cancer is an important issue to address since there
is substantial evidence that high concentrations of proteolytic
factors in primary breast cancer tissue are conducive to tumour
cell spread and metastasis (Ja ¨nicke et al, 1990). Penetrating tumour
cells focus on the proteolytic activity of the serine protease
urokinase-type plasminogen activator (uPA) secreted by tumour
cells or surrounding stromal cells to the cell surface through a
receptor for uPA (uPAR, CD87), thus facilitating extracellular
matrix degradation.
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the cell surface, the uPAR also interacts with integrins such as
vitronectin (Vn) and thus facilitates cell–matrix interactions (Wei
et al, 1994). It was demonstrated by Wei et al (1996) that the
capacity of uPAR to act as an adhesions receptor depends as well
on a functional and physical association with integrins. Urokinase
plasminogen activator receptor forms complexes with activated
integrins, presumably utilising integrin connections to the
cytoskeleton to promote stable adhesion to Vn mediated by the
distinct binding site on uPAR. Urokinase plasminogen activator
receptor/Vn interaction can be enhanced by uPA and attenuated
by the PAI-1, which binds to the somatomedin B domain of Vn
(Deng et al, 1996). In addition, uPAR is capable of modulating cell
adhesion by activating cells directly via a G-protein-coupled
receptor (Liu et al, 2002), by sequestering caveolin (Wei et al,
1999), and by affecting intracellular signalling events (Nguyen et al,
1999). Thus, uPAR is an important regulator of the adhesive
behaviour of cells.
In previous studies, we have observed that components of the
urokinase system are found not only in invasive breast cancer cells
but also in MEs, macrophages, fibroblasts and tumour cells of
DCIS (Hildenbrand et al, 1998, 2000). This suggests that uPAR
expression of MEs, located in this strategically important position,
may be involved in uPA/PAI-1-dependent tumour cell invasion.
This prompted us to perform this study on DCIS with a special
look on the expression of the urokinase system in MEs.
MATERIALS AND METHODS
In all, 60 patients with DCIS were enrolled in the study. Tissue was
obtained by surgery (either by breast preservation (n¼56) or
mastectomy (n¼4)). The patients were on average 54.6710.3
(mean7s.d.) years of age (median 53 years, range 30–79 years).
Histological types were categorised according to their architectural
patterns. Four main patterns were observed: comedo-, micro-
papillary-, cribriform- and solid type. Most DCIS showed mixed
patterns. The ‘Van Nuys (VN) Classification’ for DCIS, introduced
in 1995 by Silverstein and co-workers, was used in this study.
Group I (n¼20) consisted of non-high-grade DCIS without
comedo-type necrosis, group II (n¼16) of non-high-grade DCIS
with comedo-type necrosis and group III (n¼24) of high-grade
DCIS, irrespective of comedo-type necrosis. For all of the cases, the
mean tumour diameter was 32.2711.2mm (median 31mm, range
3–64mm). In all, 12 cases with normal (nontumour, benign)
breast tissue were also examined.
Immunohistochemistry and double immunostaining
Tumour specimens were formalin fixed and paraffin embedded.
The tissue sections were stained by the APAAP method as
described previously (Hildenbrand et al, 1998, 2000) by applying
anti-uPAR monoclonal antibody (mAb) #3936 (American Diag-
nostica, Germany), chicken polyclonal antibody (pAb) HU277 and
mAb IID7 (a kind gift from Dr. Magdolen, Luther and Schmitt, TU
Mu ¨nchen and TU Dresden, Germany); pAb HU277 is directed to
recombinant human uPAR (corresponding to amino acids 1–277
of uPAR) expressed in transfected CHO cells (Magdolen et al,
1995); mAb #3936 (IgG2a) to uPAR expressed by phorbol ester-
stimulated promyeloid U937 cells; and mAb IID7 to human
nonglycosylated uPAR polypeptide1–284 expressed in Escherichia
coli (Luther et al, 1997). Consecutive tissue sections were stained
with mAbs to alpha-actin (DAKO, Germany), anti-calponin
(BioGenex, Germany), anti-uPA (American Diagnostica, Germany,
#3688), anti-PAI-1 (American Diagnostica, Germany, #3785) and
anti-Vn (mAb 892C, Innovex, Germany).
In all cases, a double staining was performed starting with the
mAb IID7 (mAb anti-PAI-1) detected with the APAAP method,
then proceeding with mAb anti-calponin detected with the
streptavidin–biotin–POD method. For the second reaction, the
DAB (diaminobenzidine)-staining kit (Leinco, k107, Germany) and
‘metal-enhancing solution’ was used. The immunostaining is in red
(APAAP, neufuchsin) and black (streptavidin–biotin–peroxidase,
DAB plus metal-enhancing solution), and the nuclei were counter-
stained with haematoxylin (blue colour). In each case negative
controls were performed by substituting nonimmune antibodies
(IgG) for mAb #3936, pAb HU277 and mAb IID7, respectively. In
addition, the staining reaction was blocked by preincubation of
pAb HU277 with an excess of CHO-uPAR1–277 prior to the staining
reaction.
In 25 cases of DCIS and in 15 cases of normal breast tissue, a
collagen type-4/Vn double staining was performed. The sections
were incubated with mAb anti-Vn (Innovex Bioscience, Germany;
dilution 1:50), washed and incubated with Texas Red sulphonyl
chloride-conjugated rabbit anti-mouse IgG (Dianova, Hamburg,
Germany; dilution 1:1000). Sections were then incubated with
anti-collagen type-4 (DAKO, Hamburg, Germany; 100mlsection
 1)
that had been biotinylated previously (ARK biotinylating-kit;
DAKO, Hamburg, Germany). The biotin label was subsequently
visualised with FITC-conjugated streptavidin (Vector Laboratories,
Burlingame USA; dilution 1:250). Controls were incubated with
nonimmune antibodies applied at the concentration as the primary
mAb. In the controls, no specific immunolabelling was observed.
In situ hybridisation
In situ hybidisation with fluorescein-labelled oligodeoxynucleo-
tides was performed following the protocol of Hildenbrand et al
(1998, 2000). For the detection of fluorescein-labelled oligodeoxy-
nucleotides, the ‘Super Sensitive mRNA Probe Detection System’
(BioGenex, CA, USA) was used. The antisense oligodeoxynucleo-
tides (Biometra, Germany) were complementary to nucleotides
121–150, 321–350, 521–550, 717–746 and 918–947 of uPAR
mRNA and 181–210, 421–450, 661–690, 901–930 and 1081–1110
of PAI-1 mRNA (according to the nucleotide numbering of
Accession number X51675 in the EMBL database).
Laser capture microdissection of immunostained frozen
sections for mRNA analysis
Serial frozen sections (4–8mm) were cut on a standard cryostat
(Leica, Germany) with a clean blade. The unfixed tissue sections
were immediately stored at  801C until use. The frozen sections
were thawed at room temperature for 30–60s and immersed
immediately in cold acetone (5min). After fixation, the slides were
rinsed briefly in phosphate-buffered saline (PBS, pH 7.4) and
subjected to immunostaining. The immunostaining was performed
with a modified DAKO staining kit (DAKO, Germany), a three-step
streptavidin–biotin technique with prediluted monoclonal anti-
smooth muscle actin (SMA) antibodies (anti-calponin, 1:80,
BioGenex, Germany; and anti-alpha-SMA, 1:100, DAKO, Ger-
many) optimised for very short staining times. The slides were
incubated at room temperature with the primary and secondary
antibodies and an alkaline-phosphatase-conjugated antibody for
90–120s each and briefly rinsed in PBS between each step. After
colour development with 0.04% 5-bromo-4-chloro-3-indolyl-phos-
phate (Roche, Mannheim, Germany) and 0.06% nitroblue tetra-
zolium (Sigma, Mu ¨nchen Germany) for 3–5min and
counterstaining with haematoxylin for 20s, the sections were
dehydrated in graded alcohols (15s each) and xylene (2 2min)
and air-dried. After immunostaining and microscopic control of
staining quality and tissue preservation, microdissection was
performed using a laser capture microdissection microscope
(Arcturus) equipped with an infrared laser. The dehydrated tissue
section was overlaid with optically transparent caps, and cells were
captured by focal melting through laser activation. After visual
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immersed in denaturation solution (Fend et al, 1999).
RNA extraction, reverse transcription (RT)
RNA was obtained from microdissected MEs (1500–2000 cells in
each case) with the Micro RNA isolation kit (Stratagene,
Germany). The RNA pellet was redissolved in 15ml sterile DEPC-
treated water and incubated with 1ml of RNAse inhibitor (PE
Applied Biosciences, Germany) and 20U of DNAse I (GenHunter,
Germany) for 2h at 371C in a total volume of 20ml. The amount
and purity of RNA was calculated by using an Agilent Bioanalyser
2100.
The RT reaction was carried out in a total volume of 40ml:
1 RT buffer (500mM deoxynucleotide triphosphates, 3mM ran-
dom primers, 60U of RNasin and 200U of Superscript RNAse H
 
(Invitrogen)). To this mixture, we added 1mg of total RNA. The
reaction was allowed to proceed for 60min at 371C followed by
5min at 951C and a subsequent rapid cooling on ice. The cDNA
was stored at  201C until further use.
After re-extraction of RNA, RT was performed using 12mlo f
total RNA, 2.5mM random hexameres, 25mM dNTPs and 100U of
MMLV reverse transcriptase (Invitrogen, Germany). For each
sample, a mock reaction without the addition of reverse
transcriptase was performed.
Qualitative and quantitative cDNA amplification
A measure of 1ml of the uPAR cDNA product was amplified in a
thermal cycler (Autogene II Grant, Germany) for 35 cycles
consisting of 60s at 951C, 90s at 551C and 3min at 721C. Taq
polymerase was obtained from Perkin-Elmer Cetus and used
according to the supplier’s instructions. The following primers
were based on the published uPAR (Casey et al, 1994) and PAI-1
(Ginsburg et al, 1986) sequence and synthesised by MWG Biotech,
Germany: uPAR sense, 50-CATGCAGTGTAAGACCAACG-30; uPAR
anti-sense, 50-CTCTCACAGCTCATGTCTGATGAGCCAC-30; PAI-1
sense, 50-ACACCCTCAGCATGTTCATT-30; and PAI-1 anti-sense,
50-CTCGATCTTCACTTTCTGCA-30.
The amplification products showed the expected size of 311
(uPAR) and 290 (PAI-1) base pairs. Appropriate negative controls
including amplification of the mock RT reaction product were
performed in each run. The polymerase chain reaction (PCR)
products were separated on a 2% agarose gel stained with ethidium
bromide.
Real-time PCR was performed in a LightCycler instrument using
LC-Fast Start Reaction Mix SYBR Green I (Roche Diagnostics).
Polymerase chain reaction amplification was carried out in a final
volume of 10ml containing 1ml of cDNA sample; 1.2ml MgCl2
(25mM); 0.2ml of PAI-1 primers (25mM each); and 1ml LC FastStart
DNA Master SYBR Green I/Enzyme Mix (including Taq DNA
polymerase, reaction buffer and deoxynucleotide triphosphate
mixture). After an initial step of 10min at 951C (cDNA
denaturation/HotStart-Taq polymerase activation), 40 amplifica-
tion cycles were performed: 15s at 951C, 5s at 581C and 15s at
721C.
After PCR, a melting curve was created by increasing the
temperature from 61 to 991C with a temperature transition rate of
0.11Cs
 1. Each PCR experiment was performed in triplicate.
For every LightCycler run, a standard curve was generated by
the detection of the crossing point (CP) of each standard. The
concentrations of unknown samples were then calculated by
comparing their CPs to the standard curve.
RESULTS
We have studied 60 different cases of DCIS, classified according to
the ‘VNs Classification’ introduced by Silverstein et al (1995), for
the expression and synthesis of uPAR by in situ hybridisation and
immunohistochemistry. All tumour tissue sections were probed
for the presence of uPAR mRNA by in situ hybridisation using
fluorescein-labelled antisense oligodeoxynucleotides. With no
exception, MEs, tumour cells, macrophages, fibroblasts and
endothelial cells showed a positive reaction with the antisense
probe (Figure 2G and H). Corresponding results were found in 12
cases with normal (nontumour) breast tissue. Epithelial cells, MEs
as well as stromal cells showed a positive reaction with the
antisense probe.
All types of DCIS were reacted with three different types of
antibodies to uPAR (IID7, HU277, #3936; see Table 1a). In 56 of the
cases (18 grade 1; 14 grade 2; 24 grade 3) MEs were stained by mAb
IID7, 41 of those specimens (15 grade 1; 12 grade 2; 14 grade 3)
reacted with pAb HU277 and 39 of those (14 grade 1; 11 grade 2; 14
grade 3) showed immunoreactivity of MEs with mAb #3936
(Figures 1A, B and 2C, D). Likewise, the DCIS were screened for
the reactivity of tumour cells with the various antibodies; mAb
IID7-stained tumour cells in the same 56 specimens (18 grade 1; 14
grade 2; 24 grade 3) in which MEs showed a positive reaction. In 50
specimens (15 grade 1; 15 grade 2; 20 grade 3) within this group
Table 1 Anti-uPAR- and anti-PAI-1 immunoreactions in 60 cases of DCIS (a) and 12 cases of normal (nontumour) breast tissue (b)
Anti-uPAR IID7 Anti-uPAR HU277 Anti-uPAR 3936 Anti-PAI-1
(a) DCIS, n¼60
a
Myoepithelial cells 56 (18/14/24) 41 (15/12/14) 39 (14/11/14) 34 (2/8/24)
Tumour cells 56 (18/14/24) 50 (15/15/20) 31 (11/10/10) 56 (19/14/23)
Macrophages 60 60 60 60
Fibroblasts 60 60 60 60
Endothelial cells 56 (17/16/23) 38 (14/10/14) 0 60
(b) Normal breast tissue, n¼12
b
Myoepithelial cells 10 8 5 1
Epithelial cells 10 7 4 1
Macrophages 12 12 12 12
Fibroblasts 12 12 12 12
Endothelial cells 7 4 0 12
uPAR¼urokinase plasminogen activator receptor; PAI-1¼plasminogen activator inhibitor; DCIS¼ductal carcinoma in situ. For anti-uPAR immunoreaction three different
antibodies were used: mAb IID7, pAb HU277 and mAb 3936.
aThe VNs Classification for DCIS (n¼60) was used in this study: group I (VN G1, n¼20) consisted of non-high-
grade DCIS without comedo-type necrosis; group II (VN G2, n¼16) of non-high-grade DCIS with necrosis; and group III (VN G3, n¼24) of high-grade DCIS, irrespective of
comedo-type necrosis. Behind the number of positive cases the results of group I, -II and III are given within parantheses (group I/group II/group III).
bImmunohistological results of
12 cases with normal (nontumour) breast tissue.
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grade 1; 10 grade 2; 10 grade 3) tumour cells showed positive
immunoreactions using mAb #3936. In all of the cases, fibroblasts
and macrophages were stained to various degrees by any of the
antibodies. Endothelial cells showed a positive immunoreaction in 56
specimens (17 grade 1; 16 grade 2; 23 grade 3) using mAb IID7 and
in 38 cases (14 grade 1; 10 grade 2; 14 grade 3) using pAb HU277.
With mAb #3936, no reaction of endothelial cells was seen at all.
In all 12 normal (non-tumour) breast tissue specimens,
macrophages and fibroblasts were stained by any of the antibodies
Figure 1 (A) Anti-uPAR HU277 immunoreaction of a high-grade DCIS. Myoepithelial cells show a strong staining (arrows) and tumour cells only a faint
immunoreaction. Macrophages (arrowhead) are also positive. (B) Anti-uPAR IID7 immunoreaction of a high-grade DCIS. Myoepithelial cells show a strong
immunoreaction (arrows) and tumour cells and endothelial cells are negative. Macrophages express the uPAR antigen (arrowhead). (C) Anti-PAI-1
immunoreaction of a high-grade DCIS. Tumour cells, endothelial cells (arrow) and stromal cells (arrowhead) are positive. The myoepithelial cell layer is
absent; in corresponding tissue sections no MEs in this duct were observed using anti-calponin and anti-SMA antibodies. (D) Normal (nontumour) breast
tissue stained for anti-uPAR IID7; MEs, epithelial cells and endothelial cells (arrow) show a strong immunoreaction, stromal cells (macrophages and
fibroblasts) (arrowheads) are also positive. (E) Double staining of normal (nontumour) breast tissue stained for anti-uPAR IID7 (red colour) and anti-SMA
(black colour); MEs show an immunoreaction for both anti-uPAR and anti-SMA. (F) Normal (nontumour) breast tissue stained for anti-PAI-1; in both
images, the ducts (MEs and epithelial cells) are negative, whereas endothelial cells (arrows) and stromal cells (arrowheads) show positive immunoreactions.
(G, H) Nonisotopic in situ hybridisation using fluorescein-labelled oligodeoxynucleotides complementary to PAI-1 mRNA in a non-high-grade DCIS with
necrosis; (G) antisense probe: a distinct reaction in MEs (arrows) and tumour cells, stromal cells and endothelial cells (arrowhead) is observed; (H)n o
reaction is seen with the sense probe.
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y(see Table 1b). In 10 of the specimens, MEs were stained by mAb
IID7, eight specimens of those reacted with HU277 and five of
those with mAb #3936. In 10 of the tissue sections, normal
epithelial cells stained with mAb IID7 (Figure 1D), and in seven
cases, epithelial cells showed a positive immunoreaction using pAb
HU277. In only four cases, epithelial cells were positive with mAb
#3936. Endothelial cells of normal breast tissue stained with mAb
IID7 (7 specimens) and pAb HU277 (4 specimens).
In 20 cases of high-grade DCIS and in eight cases of normal
breast tissue, a double immunostaining was performed using mAb
IID7 and anti-calponin. In all cases, MEs showed a positive
immunoreaction with both antibodies (Figures 1E and 2F).
In 15 specimens of DCIS (five grade 1; five grade 2; five grade 3;
all anti-uPAR positive) and in eight cases of normal breast tissue
frozen sections and anti-SMA immunoreactions were performed
followed by a laser capture microdissection of the MEs. RNA from
Figure 2 (A–D) Represent one intermediate-grade DCIS stained with mAb anti-uPA (A), anti-PAI-1 (B) and anti-uPAR IID7 (C, D). (A) Myoepithelial
cells (arrows) show a positive anti-uPA immunoreaction, tumour cells show only a faint reaction; (B) same DCIS as in image B, showing an incomplete ME
layer with a strong anti-PAI-1 immunoreaction; tumour cells show a faint immunoreaction. (C, D) Same DCIS as in images A and B stained with mAb anti-
uPAR IID7; the ME layer in image C is absent and the tumour cells are partly detached from the bm; MEs in image D show a strong anti-uPAR
immunoreaction; tumour cells in both images are weakly anti-uPAR positive; luminal macrophages (arrow) in image C strongly express the uPAR antigen.( E)
Represents a high-grade DCIS double stained for anti-PAI-1 (red colour) and anti-SMA (black colour); MEs are positive for both anti-PAI-1 and anti-SMA,
tumour cells, stromal cells (arrowhead) and endothelial cells (arrow) strongly express the PAI-1 antigen. (F) Represents a high-grade DCIS double stained
for anti-uPAR IID7 (red colour) and anti-SMA (black colour); MEs are positive for both anti-uPAR and anti-SMA; tumour cells and stromal cells strongly
express the uPAR antigen. (G, H) In situ hybridisation using fluorescein-labelled oligodeoxynucleotides complementary to uPAR-mRNA in a non-high-grade
DCIS (grade 1); (G) antisense probe: a distinct reaction in MEs, tumour cells, stromal cells and endothelial cells is observed; (H) no reaction is seen with
sense probe.
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performed. In all cases, the expected 311bp PCR product was
obtained (Figure 3B). In addition, we have performed PAI-1-
specific real-time PCR on RNA samples derived from ME cells of
normal breast tissue, low- and high-grade DCIS. Each experiment
was performed in triplicate. Comparison of the calculated mRNA
amounts in each group revealed only slight changes in PAI-1
mRNA (MEnormal breast tissue: 22.12–24.8ng; MElow-grade DCIS:
19.46–22.48ng; MEhigh-grade DCIS: 24.58–33.72ng).
Furthermore, we have studied the PAI-1 expression by
immunohistochemistry and in situ hybridisation of 60 DCIS and
12 specimens of normal breast tissue. Myoepithelial cells stained
with mAb PAI-1 in 34 cases of DCIS (Figure 2E), of those 24
specimens were grade 3, eight specimens were grade 2 and two
cases were grade 1. In 56 DCIS (19 grade 1; 14 grade 2; 23 grade 3),
a positive immunoreaction of tumour cells was observed
(Figure 1C). In all cases, macrophages, fibroblasts and endothelial
cells stained with mAb PAI-1. In only one specimen of normal
breast tissue MEs and epithelial cells showed a weak positive anti-
PAI-1 immunoreaction. In all normal breast tissue specimens
stromal cells and endothelial cells stained with mAb PAI-1
(Figure 1F). All tumour tissue sections were probed for the
presence of PAI-1 mRNA by in situ hybridisation using
fluorescein-labelled oligodeoxynucleotides. With no exception,
macrophages, fibroblasts and endothelial cells showed a positive
reaction with the antisense probe. Myoepithelial cells showed
positive reactions in 34 cases (two grade 1; eight grade 2; 24 grade
3) and tumour cells in 56 cases (18 grade 1; 15 grade 2; 23 grade 3)
(Figure 1G and H). In 15 high-grade DCIS anti-PAI-1-/anti-
calponin double immunostaining was performed. In all high-grade
DCIS, a double staining (anti-PAI-1: red colour; anti-calponin:
black colour) of MEs was observed (Figure 2E).
Double staining with anti-Vn and anti-collagen type-4 mAbs
revealed an association of both proteins in bm’s of breast ducts
and blood vessels in all examined DCIS cases (n¼10) (Figure 4).
In eight cases, the tumour cells and stroma showed a weak positive
anti-Vn immunoreaction.
DISCUSSION
Two epithelial cell types line the entire normal duct and lobular
system of the human breast. There is an inner ‘luminal’ cell layer
and an outer ME layer. The MEs of the breast ducts and breast
glands may play a special role concerning the invasion of tumour
cells because of their important anatomic location between the bm
and the epithelial cells/noninvasive tumour cells of DCIS. The ME,
which lies on the epithelial side of the bm, is thought to contribute
considerably to both the synthesis and remodelling of this
structure. The ME also lies in direct juxtaposition to normally
proliferating and differentiating cells in healthy breast tissue and
to abnormally proliferating and differentiating epithelial cells in
precancerous lesions of the breast (Lakhani and O’Hare, 2001). In
this study, we have demonstrated by multimodal methods that
uPAR protein and mRNA is expressed in most MEs of the normal
duct and lobular system and in DCIS. This is an important issue to
address since the uPA system plays an important role in matrix
degradation and invasion. In addition to promoting cell migration
by focusing uPA proteolytic activity to the cell surface, uPAR can
physically be associated with another ligand, Vn, mediating cell
adherence to the extracellular matrix such as bm. We have
demonstrated by double staining that the extracellular matrix
protein Vn and collagen type-4 are colocalised in the bm of DCIS
and normal breast ducts/acini. In Figure 4 (double staining of a
DCIS using anti-collagen type-4 and anti-Vn mAb), one can see
that both proteins are associated within the bm of a breast duct
and vessel walls. This is no surprising result, since a strong
interaction of Vn and collagen type-4 in vitro is well known (Gebb
et al, 1986). Furthermore, a colocalisation of both proteins is
known in the bm of the kidney tubulus and of vascular bm’s (Falk
et al, 1987; Sawa et al, 1993). The presence of Vn within the bm
and the expression of uPAR in MEs of both DCIS and normal
breast glands suggests an important cell–matrix interaction, which
regulates the cell adhesion and detachment. uPA is the physiolo-
gical activator of this ‘Vn’ receptor, which means that uPA
stabilises the Vn-uPAR binding and thereby the cell–matrix
contact. PAI-1 is not only a protease inhibitor but also resolves the
Vn-uPAR binding and releases the cells from the cell–matrix
contact (Wei et al, 1996). Therefore, uPAR in MEs of the breast
may play a multifunctional role. In the normal breast tissue uPAR
is necessary for the physiological shedding of epithelial and MEs.
By focusing the proteolytic enzyme uPA on the cell surface, uPAR
of MEs take part in the remodelling of the bm.
In our study, the MEs express PAI-1 in all high-grade DCIS
(n¼24), whereas anti-PAI-1 immunoreaction of MEs in non-high-
grade DCIS without comedo-type necrosis (VNs group I) was
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Figure 3 (A) Quantitative RT–PCR of mRNA derived from micro-
dissected MEs of normal breast tissue, low- and high-grade DCIS using PAI-
1-specific primers. From each group one case was selected and a
LightCyclert analysis was performed in triplicate. The amount of PAI-1
mRNA was calculated by assorting each CP to a standard curve. (B) The
RNA of MEs (DCIS and normal breast tissue) was isolated, reverse
transcriptase reaction followed by a PCR using uPAR primers (see Materials
and methods) was performed. The RT–PCR reveals a 311bp product in
both probes (DCIS and normal breast tissue); without RT reaction no
product was received.
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comedo-type necrosis (VNs group II) in eight of 16 cases. Analysing
total RNA of MEs derived from one low- and one high-grade DCIS
and one case of normal breast tissue by real-time RT–PCR exhibited
no significant differences in PAI-1 expression (Figure 3A). One case
with anti-PAI-1 immunoreaction of MEs was observed in normal
breast ducts/glands. On the contrary, uPA expression was found in
nearly all (11 of 12) MEs of the normal breast tissue and only in six
of 24 cases in MEs of high-grade DCIS, whereas the tumour cells of
the high-grade DCIS showed a positive anti-uPA immunoreaction in
18 of 24 cases. These results seem to us as the expression of uPA and
PAI-1 in MEs of high-grade DCIS and in MEs of normal breast tissue
is inversely regulated, whereas the uPAR expression of MEs is
relatively constant in all examined lesions.
In one case of intermediate-grade DCIS, a few ducts showed an
incomplete ME layer expressing uPAR and PAI-1 (Figure 2A–D). In
this case, a few ducts had a complete loss of the ME layer. A moderate
anti-uPA immunoreaction of MEs was found. In this interesting case,
we speculate that high levels of PAI-1 and low levels of uPA in MEs
are involved in the Vn-mediated detachment of the MEs.
A detailed analysis by Sternlicht and Barsky (1997) revealed that
MEs tend to express low levels of matrix-degrading proteinases
(e.g. matrix metalloproteinases-2 and -9 and uPA), but relatively
high levels of proteinase inhibitors (tissue-inhibitor metallopro-
teinase-1, protease nexin II/b-amyloid precursor protein, PAI-1)
and the tumour suppressor maspin. They conclude that MEs
regulate the progression of DCIS to invasive cancer by inhibiting
cell invasion. Sternlicht and Barsky (1997) suggest that PAI-1 does
not contribute to the anti-invasive phenotype of MEs or,
conversely, to a highly invasive and metastatic phenotype of
tumour cells. In fact, PAI-1 has been correlated directly with uPA
expression and poor prognosis in breast cancer (Schmitt et al, 1997).
This assumption is in accordance with our findings since in our
study PAI-1 expression of MEs was found in all high-grade DCIS.
It is possible that the uPA, PAI-1 and uPAR expression of MEs in
DCIS is mediated by a paracrine action of tumour cells and that
uPA/PAI-1 play an important role in the cell–matrix interaction
(cell adhesion/detachment) of MEs. PAI-1 may be an important
component in the detachment of MEs, since PAI-1 is able to
attenuate the cell–matrix interaction by resolving the uPAR/Vn
binding. Although the role of PAI-1 acting as cell detachment factor
could not be demonstrated in our study, we speculate that the loss
of the anti-invasive ME layer in DCIS may be triggered by PAI-1
and could be an early sign of subsequent tumour cell infiltration.
In normal breast tissue uPAR of MEs may contribute to the
remodelling of the bm by focusing uPA proteolytic activity on the
myoepithelial surface. uPA, uPAR and PAI-1 in epithelial cells of
normal breast tissue may be involved in the physiological shedding
of the glands.
ACKNOWLEDGEMENTS
This research was supported by the Deutsche Krebshilfe Dr
Mildred Scheel Stiftung fu ¨r Krebsforschung, 10-1507H, Germany,
American Diagnostica Germany, and by a grant from the Faculty of
Clinical Medicine, University of Heidelberg, Mannheim, Germany.
REFERENCES
Casey JR, Petranka JG, Kottra J, Fleenor DE, Rosse WF (1994) The structure
of the urokinase-type plasminogen activator receptor-gene. Blood 84:
1151–1156
Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ (1996) Is
plasminogen activator inhibitor-1 the molecular switch that governs
urokinase receptor-mediated cell adhesion and release? J Cell Biol 134:
1563–1571
Falk RJ, Podack E, Dalmasso AP, Jennette JC (1987) Localization of S
protein and its relationship to the membrane attack complex of
complement in renal tissue. Am J Pathol 127: 182–190
Figure 4 Immunofluorescence double staining of a high-grade DCIS with mAb anti-Vn ((A) red signal) and anti-collagen type-4 ((B) green signal); (C)
both immunoreactions are associated within the bm of the breast duct and of a blood vessel; (D) DCIS double immunolabelled for Vn and collagen type-4
with a 10-pixel shift of the red signal (collagen type-4), revealing clearly a green and red signal in the bm’s.
uPAR and PAI-1 expression in myoepithelial cells
R Hildenbrand and N Arens
570
British Journal of Cancer (2004) 91(3), 564–571 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yFend F, Emmert-Buck MR, Chuaqui R, Cole K, Lee J, Liotta LA, Raffeld M
(1999) Immuno-LCM: laser capture microdissection of immunostained
frozen sections for mRNA analysis. Am J Pathol 154: 61–66
Gebb C, Haymann EG, Engvall E, Ruoslahti E (1986) Interaction with
vitronectin and collagen. J Biol Chem 261: 16698–16703
Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L,
Dano K, Lebo RV, Gelehrter TD (1986) cDNA cloning of human
plasminogen activator–inhibitor from endothelial cells. J Clin Invest 78:
1673–1680
Hildenbrand R, Glienke W, Magdolen V, Graeff H, Stutte HJ, Schmitt M
(1998) Urokinase receptor localization in breast cancer and benign
lesions assessed by in situ hybridization and immunohistochemistry.
Histochem Cell Biol 110: 27–32
Hildenbrand R, Leitz M, Magdolen V, Luther T, Albrecht S, Graeff H, Stutte
HJ, Bleyl U, Schmitt M (2000) Validation of immunolocalization of the
urokinase receptor expression in ductal carcinoma in situ of the breast:
comparison with detection by non-isotopic in-situ hybridization.
Histopathology 36: 499–504
Ja ¨nicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Go ¨ssner W,
Graeff H (1990) Urokinase-type plasminogen activator (uPA) antigen is a
predictor of early relapse in breast cancer. Fibrinology 4: 69–78
Lakhani SR, O’Hare MJ (2001) The mammary myoepithelial cell –
Cinderella or ugly sister? Breast Cancer Res 3: 1–4
Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L (2002) EGFR is a transducer
of the urokinase receptor initiated signal that is required for in vivo
growth of a human carcinoma. Cancer Cell 1: 445–457
Luther T, Magdolen V, Albrecht S, Kasper M, Riemer C, Kessler H, Graeff
H, Mu ¨ller M, Schmitt M (1997) Epitope-mapped monoclonal antibodies
as tools for functional and morphological analyses of human urokinase
receptor in tumor tissue. Am J Pathol 150: 1231–1244
Magdolen V, Rettenberger P, Lopens A, Oi H, Lottspeich F,
Kellermann J, Creutzburg S, Goretzki L, Weidle U, Wilhelm O, Schmitt
M, Graeff H (1995) Expression of the human uPA receptor (uPA-R)
in E. coli and CHO cells: purification of the recombinant proteins
and generation of polyclonal antibodies in chicken. Electrophoresis 16:
813–816
Nguyen DHD, Catling AD, Webb DJ, Snakovic M, Walker LA, Somlyo AV,
Weber MJ, Gonias SL (1999) Myosin light chain kinase funtions
downstream of Ras/ERK to promote migration of urokinase-type
plasminogen activator-stimulated cells in an intergrin-selective manner.
J Cell Biol 146: 149–164
Page D, Dupont W, Rogers L, Landenberger M (1982) Intraductal
carcinoma of the breast: follow up after biopsy only. Cancer 49: 751–758
Sawa H, Sobel BE, Fuji S (1993) Potentiation by hypercholesterolemia of the
induction of aortic intramural synthesis of plasminogen activator
inhibitor type-1 by endothelial injury. Circ Res 73: 671–680
Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U,
Ulm K, Ho ¨fler H, Ja ¨nicke F, Graeff H (1997) Clinical impact of the
plasminogen activation system in tumor invasion and metastasis:
prognostic relevance and target for therapy. Thromb Haemost 78: 285–296
Silverstein MJ (1998) Ductal carcinoma in situ of the breast. BMJ 317:
734–739
Silverstein MJ, Poller DN, Waisman JR (1995) Prognostic classification of
breast ductal carcinoma in situ. Lancet 245: 1154–1157
Sternlicht MD, Barsky SH (1997) The myoepithelial defense: a host defense
against cancer. Med Hypotheses 48: 37–46
Sternlicht MD, Kedeshian P, Shao ZM, Safarians S, Barsky SH (1997) The
human myoepithelial cell is a natural tumor suppressor. Clin Cancer Res
3: 1949–1958
Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV,
Chapman HA (1996) Regulation of integrin function by the urokinase
receptor. Science 273: 1551–1555
Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA (1994)
Identification of the urokinase receptor as an adhesion receptor for
vitronectin. J Biol Chem 269: 32380–32388
Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA (1999) A role for caveolin
and the urokinase receptor in integrin-mediated adhesion and signaling.
J Cell Biol 144: 1285–1294
uPAR and PAI-1 expression in myoepithelial cells
R Hildenbrand and N Arens
571
British Journal of Cancer (2004) 91(3), 564–571 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y